Myeloma 2017 | Dendritic cell vaccine for MM: progress so far
Cancer immunotherapy is a very active area of research at the moment, with the potential to treat a cancer long-term by stimulating an individual’s immune system to recognize and destroy cancer cells. In this interview, David Avigan, MD, of Beth Israel Deaconess Medical Center, Boston, MA, discusses the development of a dendritic cell vaccine for multiple myeloma (MM), which has yielded promising results and led to a nationwide randomized follow up study. Dr Avigan also touches upon potential adjuvant therapies that could aid a vaccine in modulating the immune response and reducing relapse rates, such as microRNAs or effector cells. This interview was recorded at the Myeloma 2017 meeting held in Edinburgh, UK.
Get great new content delivered to your inboxSign up